Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis, primarily affecting the lungs but also capable of extrapulmonary involvement. It remains a major global health burden.
New research reveals how TB bacteria resist drugs via PE/PPE proteins and evade immune defenses by stiffening cell membranes. TB remains the leading infectious killer, with 1.23 million deaths in 2024.
RCB Faridabad announces three openings: a ₹1.30L/month Post Doc EIR fellowship, a Project Associate II for TB research, and an apprenticeship for life sciences graduates. Deadlines: Feb 25, Jun 8-9, Jul 24, 2026.
A single-center study of 95 chronic kidney disease patients on hemodialysis found the Cy-TB skin test agreed completely with standard IGRA testing for latent tuberculosis, with an overall prevalence of 4.2%. Early dialysis phase (<6 months) was a strong predictor of positivity, suggesting a potential priority screening window, though larger confirmatory studies are needed.
Trial: VPM1002/Immuvac show limited overall TB protection but up to 50.4% efficacy vs extrapulmonary TB. Modeling: blocking asymptomatic TB key to long-term vaccine impact. Also: STEP-TB safety study and CDC Asia funding.
Kenya is building local vaccine manufacturing capacity through a WHO-supported mRNA technology transfer project and a three-phase strategy focused on childhood vaccines. The country aims to reduce reliance on imports, with a fill-and-finish facility in Embakasi expected by 2027 and first locally produced vaccines by 2028.
Three advances in TB diagnostics: a portable $300 device delivering results in 30 minutes, a Quick DNA kit detecting drug resistance in 5 minutes, and an ultrasensitive test finding TB DNA in 12-16% of hospitalized US patients.
India launches ₹10,000 crore Biopharma SHAKTI initiative to transform from generics manufacturing to innovation-led biologics leadership. The national mission aims to capture 5% of global biopharmaceutical market while addressing structural challenges in drug discovery and AI adoption.
A vaccine and two novel tuberculosis treatments are advancing through Phase III trials, marking renewed momentum in TB research. Tuberculosis claims over 1.25 million lives annually with 10.6 million new cases in 2023, while current treatments face challenges of high pill burden, toxicity, and rising resistance.
The World Health Organization has recommended new portable TB diagnostic tests that deliver results in under an hour, while researchers developed an inhalable nanoparticle treatment that could replace daily pills. TB remains the world's deadliest infectious disease, killing 1.2 million people in 2024 despite being preventable and curable.
Researchers have developed an inhalable nanoparticle system for delivering rifampin directly to the lungs, potentially reducing tuberculosis treatment from daily to once-weekly dosing while lowering side effects and improving drug effectiveness.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07784894 |
A Study to Investigate the Repeat-dose Pharmacokinetics of a Combined Oral Contraceptive When Given Alone and in Combination With Ganfeborole in Female Participants of Non-childbearing Potential |
NOT_YET_RECRUITING | PHASE1 |
| NCT07735754 |
A Step Forward for Unraveling the Immune Mechanisms and Tools for Tuberculosis Spectrum Management |
NOT_YET_RECRUITING | |
| NCT07708779 |
A Phase I Study Investigating the Local Tolerability and Pharmacokinetics of Isoniazid (INH) Inhalation by Wet Nebulization in Patients With Tuberculosis |
RECRUITING | PHASE1 |
| NCT07687121 |
Shaping a Community-based Pathway to Improve TB Surveillance Among African and Hindustan Immigrants Experiencing Vulnerabilities |
NOT_YET_RECRUITING | |
| NCT07677904 |
Tuberculosis Clinical Registry in Europe |
NOT_YET_RECRUITING | |
| NCT07668479 |
Rifapentine-Based Shorter Regimens for Tuberculosis and TB Infection in Kazakhstan |
NOT_YET_RECRUITING | |
| NCT07656012 |
Re-evaluating the Duration in Children of TB Treatment |
NOT_YET_RECRUITING | PHASE2 |
| NCT07647107 |
A Phase I Study of Lipovaxin Tuberculosis Vaccine in Adult Healthy Populations |
NOT_YET_RECRUITING | PHASE1 |
| NCT07638670 |
Effect of Mycobacterial Infection on Immune Status |
RECRUITING | |
| NCT07609264 |
TB Stigma in the UK: Patients Experiences and Everyday Responses |
NOT_YET_RECRUITING |
